There's a debate to be had about the latest genome-editing data

The first look at zinc finger genome editing in real human patients is here and the clinical trials results are ... confusing.

Two patients with a rare inherited disease are showing early signs of improvement after being injected with the groundbreaking genome-editing fix known as SB-913 from Sangamo Therapeutics.

That’s the encouraging news, but of course, there’s a caveat: Sangamo is unable so far to show data conclusively linking its genome-editing therapy to the improvements seen in patients. The biotech is confident it will be able to produce these confirmatory data eventually, but it’s going to take more time.

Until then, it’s a genomic-editing muddle that STAT's Adam Feuerstein tried to sort out.

Read more.